MedTrace Logo

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

NCT00886821 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2017-04-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

CVX-096

Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886821 on ClinicalTrials.gov